The FDA's clearance of Relaxera's IND application validates the company's preclinical data package and the clinical development strategy for relaxin-2 in Heart Failure with Preserved Ejection Fraction and in Atrial Fibrillation. The submission is supported by a comprehensive body of pharmacological, toxicological, and translational evidence demonstrating the safety profile and mechanistic rationale of synthetic human [...]

Relaxera is designing a clinical phase II study demonstrating the beneficial and pleiotropic effects of relaxin-2 in patients with heart failure. Title of the study: Synthetic human relaxin-2 for patients with chronic symptomatic heart failure with preserved and mildly reduced ejection fraction (HFpEF, HFmrEF) and high fibrosis risk: A multi-center, double-blind, randomized, parallel-arm phase II [...]